IN B009
Alternative Names: IN-B009; SARS-CoV-2 Vaccine - HK inno.NLatest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator HK inno.N
- Class Antivirals; COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in South Korea (IM, Injection)
- 30 Jun 2021 Phase-I clinical trials in COVID-2019 infections (Prevention) in South Korea (IM) before Hune 2021 (HK inno.N pipeline, June 2021)
- 30 Nov 2020 IN B009 is available for licensing as of 15 Jan 2021. http://www.inno-n.com/eng/business/out_licensing.asp (HK inno.N Website, January 2021)